Increasing Transparency in Generic Drug Applications Act

S. 1302 would amend federal drug approval law to increase transparency in how the FDA evaluates generic drug applications. The bill would require the Secretary of Health and Human Services to issue guidance within one year explaining how the FDA determines whether a generic drug is qualitatively and quantitatively the same as the original brand-name drug. If a proposed generic drug differs from the original, the FDA would need to identify which specific ingredients cause the difference and explain the extent of any quantitative deviations. The bill would also establish that once the FDA approves a generic drug as equivalent, that determination cannot be changed or rescinded unless the original drug's formulation has been modified for safety reasons or a clear error is identified.

Proponents argue the bill would streamline the generic drug approval process by eliminating uncertainty for manufacturers, potentially allowing lower-cost generic medications to reach consumers faster. The bill is currently in committee and has not yet been voted on by the full Senate.